Framework
WAFL: Waste, Abuse, Fraud & Lack of Knowledge.
The four categories every dollar of pharmacy loss falls into. What they mean. What they cost. How Inspector AI measures each one.
WAFL is both an acronym and a framework. Waste. Abuse. Fraud. Lack of knowledge. These four categories cover every way money leaks out of a pharmacy benefit program — and the detection strategy is different for each. Most vendors collapse them into one bucket called fraud and miss the other three. The fourth is the category everyone forgets: claims approved by doctors and reviewers who did not know the drug was clinically inappropriate or that it violated the plan rules. Not malicious. Just uninformed. The percentages and dollar figures on this page are observations from a real Latin American pharmacy benefit program of roughly 50,000 subscribers over one production year — not projections, not industry averages. Your book will look different.
Waste
Definition: overuse and over-utilization of legitimate medications. Not fraud, not malicious — just more drug than the patient needs, for longer than the patient needs it. What it looks like: early refill patterns where a thirty-day supply is dispensed every twenty-five days; cumulative dose totals exceeding therapeutic safety limits on long-term therapy; duplicate therapy where two drugs in the same class are prescribed by different specialists who did not coordinate. Observed impact on our 50K book: 20.3% of pharmacy spend. One in sixteen subscribers was flagged for early refill. 433 subscribers exceeded safe cumulative-dose limits. Early refill alone drove $176,000 of observed loss in one year; cumulative dose added another $13,000. How Inspector AI detects it: peer-comparison baselines for utilization rates, cumulative-dose tracking against therapeutic ceilings, plan-rule enforcement on refill timing.
Abuse
Definition: legal but exploitative. Branded dispensing when a clinically equivalent generic exists, substitution-economics arbitrage, rules technically followed but spirit violated. What it looks like on our 50K book: 96.8% of pharmacy spend went to branded drugs. 71% of those branded products had a generic available. Under 5% were actually dispensed as generic. Of the substitutions that could have been made, 99.8% would have been clinically safe. The gap between what was allowed and what was done is the abuse category. Observed impact on our 50K book: 10.8% of pharmacy spend. Generic substitution opportunity alone was $4.53 million of observed loss in one year — the single largest category in the WAFL breakdown on this book by dollar value. How Inspector AI detects it: substitution trees for branded-to-generic mapping, plan-rule enforcement on generic-first policies, audit trails showing which substitutions were declined and why.
Fraud
Definition: intentional deception. Cloned prescriptions submitted across multiple pharmacies, same-molecule re-authorization rings where the same patient gets the same drug re-authorized through different prescribers, behavioral fraud patterns that only make sense if someone is gaming the system. What it looks like on our 50K book: one in five subscribers was affected by same-molecule re-authorization. Networks of prescribers and pharmacies with correlated fraudulent volume. Identical prescriptions appearing across patients who were not related and did not share a provider. Observed impact on our 50K book: 4.6% of pharmacy spend. Same-molecule re-authorization drove $244,000 of observed loss in one year; cloned prescriptions added another $8,000. How Inspector AI detects it: pattern-recognition across prescriber-pharmacy-patient triples, network analysis to expose coordinated rings, behavioral anomaly scoring on individual subscriber histories.
Lack of Knowledge
Definition: the category everyone forgets. Clinically inappropriate or rules-violating approvals made by doctors and reviewers who did not know the guideline. No malicious intent. Just uninformed decisions that pass review because nobody caught the mismatch. What it looks like on our 50K book: one in six subscribers received a drug with no diagnostic justification. 80% of the clinical flags Inspector AI raised were complete therapeutic-area mismatches — the drug and the diagnosis were not in the same medical category. The approver did not know the drug was wrong for that diagnosis, and nothing in the workflow forced them to check. Observed impact on our 50K book: 7.3% for clinical mismatch plus 0.4% for financial anomaly, for a combined 7.7% of pharmacy spend. Clinical mismatch drove $126,000 of observed loss in one year. How Inspector AI detects it: diagnosis-to-drug clinical-guideline matching, therapeutic-area classification, rules-engine enforcement on plan exclusions.
total WAFL exposure observed on a real 50,000-subscriber Latin American pharmacy book — $5.1 million of detectable loss in one year
| Waste | 20.3% |
| Abuse | 10.8% |
| Lack of Knowledge | 7.7% |
| Fraud | 4.6% |
| Total | 43.4% |
See your WAFL breakdown
A three-week proof of concept produces a full WAFL breakdown on your production pharmacy claims. No integration required. You get your own numbers, by category, on real data.
Frequently asked questions
- What is WAFL?
- WAFL stands for Waste, Abuse, Fraud & Lack of Knowledge. It is the framework Inspector AI uses to categorize pharmaceutical losses: 20.3% waste/utilization, 10.8% generic substitution opportunity, 7.3% clinical mismatch (lack of knowledge), 4.6% behavioral fraud risk, and 0.4% financial anomaly. The Lack of Knowledge category covers clinically inappropriate or rules-violating approvals made by doctors and reviewers who did not know the guideline — not malice, just uninformed decisions.
- Why does Inspector AI measure WAFL categories separately?
- Because the detection strategy is different for each. Waste is a peer-comparison and cumulative-dose problem. Abuse is a substitution-economics problem. Fraud is a pattern-recognition and network-analysis problem. Lack of Knowledge is a clinical-guideline and rules-enforcement problem. Collapsing them into one bucket called fraud hides the largest category — waste — and misses the second-largest — lack of knowledge — entirely.
- Can I see the WAFL breakdown on my own claims data?
- Yes. The three-week proof of concept produces a full WAFL breakdown on your production pharmacy claims. No integration required — we ingest a claims sample and return a WAFL report with the same category structure you see on this page, using your actual numbers.